New 'Two-Pronged' CAR-T attack shows promise for tough blood cancers
NCT ID NCT07101705
First seen Jun 26, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. OriV508 is a type of immunotherapy that uses a virus to deliver instructions to the body to make cancer-fighting cells that target two different proteins on the cancer cells. The study will enroll 40 participants to check the safety of the treatment and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OriV508 injection (a type of CAR-T cell therapy that targets two proteins on cancer cells)
- What this could lead to
- If it works, this could offer a new treatment option for people with blood cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early, small study (Phase 1) focused on safety, so it is too soon to know if it will be effective. There are risks of serious side effects like cytokine release syndrome and nervous system problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- MRI scans may reveal hidden clues to myeloma relapse risk
- Can a dual immunotherapy erase hidden myeloma cells?